Skip to main content

Aldeyra Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 27, 2026

ALDX$0.64+0.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this annual report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the Commonwealth of Massachusetts, on February 27, 2026.

ALDEYRA THERAPEUTICS, INC.
By:/s/ Todd C. Brady, M.D., Ph.D.
Todd C. Brady, M.D., Ph.D.
President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Todd C. Brady and Michael Alfieri, and each of them, as his or her true and lawful attorneys-in-fact, proxies, and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, proxies, and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies, and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1934, this annual report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Todd C. Brady, M.D., Ph.D.Chief Executive Officer and DirectorFebruary 27, 2026
Todd C. Brady, M.D., Ph.D.(principal executive officer)
/s/ Michael AlfieriHead of FinanceFebruary 27, 2026
Michael Alfieri(principal financial and accounting officer)
/s/ Richard H. Douglas, Ph. D.Chairman of the Board of DirectorsFebruary 27, 2026
Richard H. Douglas, Ph.D.
/s/ Ben Bronstein, M.D.DirectorFebruary 27, 2026
Ben Bronstein, M.D.
/s/ William ClarkDirectorFebruary 27, 2026
William Clark
/s/ Martin J. JoyceDirectorFebruary 27, 2026
Martin J. Joyce
/s/ Nancy Miller-RichDirectorFebruary 27, 2026
Nancy Miller-Rich
/s/ Gary Phillips, M.D.DirectorFebruary 27, 2026
Gary Phillips, M.D.
/s/ Neal Walker, D.O.DirectorFebruary 27, 2026
Neal Walker, D.O.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.